SymBio Pharmaceuticals Limited [4582.T]

TOKYO, May 07 (Pulse News Wire) – Symbio Pharmaceuticals Limited (4582.T) reported consolidated results for Q1 FY2026 (ending December 2026). Revenue was ¥230 million (+11.6% YoY).

Operating profit was ¥2,341 million. net profit was ¥2,401 million.

Total assets stood at ¥3.9 billion with an equity ratio of 23.9%. The full-year forecast for the current fiscal year is revenue of ¥3.9 billion (+197.5%).

Financial results — FY2026/12 (consolidated)

MetricCurrentYoY
Revenue¥233M-11.6%
Operating profit¥-2,341Mn/a
Net profit¥-2,401Mn/a

Next period forecast

Revenue

¥3,891M

+197.5%

Op. profit

¥-4,231M

n/a

Net profit

¥-4,331M

n/a

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.